No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Procter & Gamble Health Limited is an Indian entity focused on the production and distribution of pharmaceutical products and chemicals. Its extensive product portfolio includes a variety of over-the-counter (OTC) medications, as well as vitamins, minerals, and dietary supplements. The company's offerings are available under recognized brand names such as Polybion, Neurobion, Evion, Nasivion, Livogen, and Seven Seas. In addition to its domestic operations, Procter & Gamble Health Limited also exports its pharmaceutical goods to several international markets, including Sri Lanka, Nepal, Myanmar, and Maldives. Established in 1967, the company originally operated as Merck Limited, rebranding to Procter & Gamble Health Limited in May 2019. It is headquartered in Mumbai, India, and functions as a subsidiary of Procter & Gamble Overseas India B.V.
www.pghealthindia.comNo one on the platform currently holds PGHL.NS.
No tracked institution reports a position in PGHL.NS as of their last filing.
No one on the platform has traded PGHL.NS yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 90.3% | — | — | — | ||
| Rev. Growth % | 15.6% | 6.9% | ||||
| Profit Margin % | 23.2% | 19.4% | 25.4% | |||
| Free Cash Flow Margin % | 22.9% | |||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $15.6B | +15.4% | $225.00 | $210.86–$239.14 | — | 2 |
| 2028 | $17.7B | +13.3% | $256.00 | $245.76–$266.24 | — | 2 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| PGHL.NSProcter & Gamble Health Limited | $5408.00 | -0.06% | $89.8B | — |
| JLHL.BOJupiter Life Line Hospitals Limited | $275.40 | -1.27% | $91.9B | — |
| JLHL.NSJupiter Life Line Hospitals Limited | $275.55 | -1.29% | $90.3B | — |
| MEDPLUS.BOMedPlus Health Services Limited | $655.25 | -0.81% | $78.7B | — |
| MEDPLUS.NSMedPlus Health Services Limited | $656.30 | -0.58% | $78.8B | — |
| METROPOLIS.BOMetropolis Healthcare Limited | $572.30 |
Source: Financial Modeling Prep · peers by sector/industry
| -2.25% |
| $119.1B |
| — |
| METROPOLIS.NSMetropolis Healthcare Limited | $572.50 | -2.22% | $118.7B | — |